Aktiia secures $42 million in Series B funding and rebrands to Hilo, aiming to revolutionize blood pressure monitoring with its innovative, cuffless technology.
 |
| With a new brand identity and $42 million in funding, Hilo (formerly Aktiia) aims to provide accessible, accurate, and continuous blood pressure monitoring solutions globally. Image: Aktiia |
London, UK — May 2, 2025:
Hilo, formerly known as Aktiia, has raised $42 million in an oversubscribed Series B funding round, co-led by Earlybird Health and Wellington Partners, with participation from Kfund, naturalX Health Ventures, and existing investors including redalpine, Khosla Ventures, Molten Ventures, Translink Capital, and Verve Ventures. This latest funding, which brings Hilo's total financing to over $100 million, will accelerate the company’s mission to address the growing global blood pressure crisis.
The new funding will be pivotal in furthering Hilo’s expansion into new markets and enhancing its blood pressure intelligence platform, which powers its cuffless blood pressure monitoring technology. Hilo, leveraging its machine learning model trained on billions of optical signals from real-world users, aims to set new standards for clinically validated, non-invasive blood pressure monitoring.
CEO Raghav "Rags" Gupta emphasized that the funding reflects the growing confidence in Hilo's groundbreaking approach to blood pressure management: “With billions worldwide suffering from hypertension and only 20% of them controlling it effectively, the need for innovative, accessible blood pressure solutions has never been greater. Our rebrand to Hilo represents a deepened commitment to empowering users with smarter tools for health optimization.”
Hilo's unique offering has already resonated with the market, having sold over 120,000 devices globally. This success is attributed to the platform’s cuffless monitoring technology that delivers real-time, continuous readings. The platform also benefits from machine learning algorithms designed specifically for blood pressure, enabling more accurate and reliable data collection.
At the core of Hilo's offerings is its Foundation Machine Learning Model, designed to process optical signals and calibration points, improving accuracy and ensuring the device’s medical-grade precision. This innovation is helping to push forward the burgeoning cuffless blood pressure monitoring (CBPM) industry.
The rebrand to Hilo not only reflects the company’s evolving mission but also aims to make blood pressure management accessible and effortless for everyone. By eliminating the need for traditional cuffs, Hilo is positioned to revolutionize how consumers and healthcare providers monitor and manage one of the world’s most prevalent health risks.
Commenting on the investment, Christoph Massner, Principal at Earlybird Health, noted: “Hilo is perfectly positioned at the intersection of medical-grade precision and consumer-centric accessibility, which is critical as high blood pressure remains one of the leading causes of death worldwide. The combination of accuracy, ease of use, and scalability makes Hilo an essential tool for modern healthcare.”
Johannes Fischer, Managing Partner at Wellington Partners, expressed similar excitement, stating, “We believe that real-time, continuous access to blood pressure data will fundamentally change how we manage and monitor hypertension. Hilo’s technology is the future of personalized health care.”
As part of its ongoing efforts to broaden its impact, Hilo will focus on expanding into new markets and developing additional product innovations. By combining cutting-edge AI with intuitive design, Hilo is set to become a leading player in the health tech sector, enabling millions to take charge of their blood pressure and live healthier lives.